Triple-negative breast cancers (TNBC) are unlikely to respond to hormonal therapies and anti-HER2targeted therapies. TNBCs overexpress EGFR and exhibit constitutive activation of the PI3K/AKT/ mTOR signalling pathway. We hypothesized that simultaneously blocking EGFR and mTOR could be a potential therapeutic strategy for the treatment of TNBC. We examined the antitumour activity of the mTOR inhibitor everolimus combined with the EGFR tyrosine kinase inhibitor gefitinib in TNBC cell with or without activating mutations in the PI3K/AKT/mTOR signalling pathway. We demonstrated that everolimus and gefitinib induced synergistic growth inhibition in the PI3K and PTEN-mutant CAL-51 cell line but not in the PTEN-null HCC-1937 cell line. The antiproliferative effect was associated with synergistic inhibition of mTOR and P70S6K phosphorylation, as well as a significant reduction in 4E-BP1 activation in the CAL-51 cell line. We also showed that combination therapy significantly inhibited cell cycle progression and increased apoptosis in this cell line. Gene and protein expression analysis revealed significant downregulation of cell cycle regulators after exposure to combined treatment. Collectively, these results suggested that dual inhibition of mTOR and EGFR may be an effective treatment for TNBC with activating mutations of PI3K. In recent decades, clinical, immunohistochemical, and molecular studies have been used to divide breast cancer into several subtypes 1. Among these multiple subtypes, triple-negative breast cancer (TNBC) is defined by reduced expression of hormone receptors and human epidermal growth factor type 2 receptor (HER2). This type of breast cancer is unlikely to respond to hormonal therapies and anti-HER2-targeted therapies. Chemotherapy and radiation therapy are currently the only ways to treat TNBC patients, but these treatments provide a partial response with early relapse and worse prognosis 2. Clinical studies have shown that TNBC is more likely to recur in the first five years after treatment and develop multidrug resistance to chemotherapy 3,4. No second-line targeted therapy is currently approved for this type of cancer. The majority of TNBC cases are characterized by the overexpression of a receptor tyrosine kinase: epidermal growth factor receptor (EGFR). This feature has emerged as a potential therapeutic target 5. It has been reported that the frequency of EGFR overexpression in TNBC is as high as 76%, suggesting that the large majority of TNBCs are likely to benefit from anti-EGFR targeted therapies 6,7. Among the different EGFR inhibitors currently approved in oncology, gefitinib is a selective EGFR tyrosine kinase inhibitor (EGFR-TKI) indicated for the treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring activating mutations of EGFR 8. Despite the absence of EGFR mutations in TNBC, gefitinib has been evaluated in TNBC patients. Clinical studies have reported that gefitinib enhanced the growth inhibitory effect of chemotherapies, but the use of g...